We are already seeing the positive impact of these efforts, based on exceptional enrollment in the pivotal SOL-1 AXPAXLI study for wet AMD, coupled with plans for a new SOL-R repeat dosing study and ...
CEO Pravin Dugel described 2025 as "a transformative year for Ocular Therapeutix" and highlighted the advancement of two registrational studies in wet AMD, SOL-1 and SOL-R. Dugel announced, "SOL-R has ...
WASHINGTON, D.C. (Sept. 1, 2020) – Nationwide and Sol Systems today announced their joint venture, Helios Infrastructure (Helios), completed the purchase of four operating Texas solar projects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback